VGXI is a contract manufacturing organization that produces DNA plasmids under GMP for human clinical trials. With nearly 20 years experience manufacturing biopharmaceuticals, VGXI has produced over 175 batches of clinical grade DNA for trials in the U.S., Canada, Europe, Asia, and Australia. The Company’s patented AIRMIX® lysis technology enables high purity, highly concentrated plasmid formulations from 1 to 15 mg/ml allowing customers to prepare low volume and multi-plasmid formulations. Its world-class process development scientists and purpose-built GMP production facility combine to ensure the success of challenging clinical programs.